Several antidepressant concept stocks rose after the release of the heavyweight document

Depression, also known as depression disorder, can be manifested as a single or repeated depressive episode, with significant and persistent depression as the main manifestation.
prevention of depression needs to start with teenagers.
Recently, the General Office of the National Health and Health Commission issued the Work Programme on Exploring The Special Services for the Prevention and Control of Depression, calling for strengthening the prevention and treatment of depression, including depression screening in the health check-up programs for high school and college students, as well as the routine pregnancy test and post-natal visits of pregnant women, and requesting that by 2020, the public's knowledge of depression prevention and treatment in the pilot areas will reach 80%, the rate of depression consultation will increase by 50% on the existing basis, increase the treatment rate by 30%, and reduce the annual recurrence rate by 30%.
market for antidepressants is promising, according to the World Health Organization, the global incidence of depression is about 11%, about 340 million people are depressed people.
, the number of people suffering from depression in China has exceeded 95 million.
has become the third-largest disease after cardiovascular disease and cancer.
and the number of people suffering from depression continues to grow.
understand that a large part of the cost of treating depression stems from the cost of taking antidepressants.
2019, sales of end-use antidepressants in China's public medical institutions reached 9,033 million yuan, up 10.93 percent year-on-year, according to Milnet data.
with the gradual improvement of public awareness of depression, and the corresponding policies on the rate of visits, treatment rate, the domestic demand for antidepressants is expected to grow, the market prospects for development.
according to industry forecasts, china's depression treatment rate to 15% conservative estimate, China's potential depression market size of about 14 billion yuan. More than
antidepressant concept stocks rose with the release of the program, Tiansli, Fosun Pharma, Yuyuan Pharmaceuticals, Spike Group, Huahai Pharmaceuticals, Colum Pharmaceuticals, Hengrui Pharmaceuticals, Enhua Pharmaceuticals, Taiji Group and many other antidepressant concept stocks, all in september 14 after the opening of a period of time, the stock price rose sharply, and then slowly fell back.
the author learned that this year, these concerned enterprises have a lot of antidepressant products to make new progress.
, for example, Tiansli recently received the approval of the State Drug Administration issued a new Class I drug JS1-1-01 "Drug Clinical Trial Approval Notice", agreed to carry out clinical trials of depression.
it is known that JS1-1-01 is a brand new structure of 5-serotonin-dethyrene-dopamine triple ingestion inhibitor (SNDRIs), but also to promote the brain-based neurotrophic factor (BDNF) secretion, play an antidepressant role.
in the field of psychothe drugs, the company now has a right zopi clone tablets (Wenfei), hydrochloric acid phenyl sorp tablets and Shubili tablets, plus JS1-1-01 tablets, to reach 4 drugs.
fluoxetine hydrochloric acid capsules of esophate pharmaceuticals were evaluated in March this year, and are the second company to pass a consistent evaluation of hydrochloric acid fluoxetine capsules.
the drug is suitable for depression, obsessive compulsive disorder, neuropathy.
Spike Group's hydrochloric acid parrostin tablets were also evaluated in March this year by generic consistency, and are used to treat depression, obsessive compulsive disorder, panic disorder, social terror/social anxiety disorder associated with or without square terror.
TaiJi Group announced on the evening of April 21st that the company's declaration of "hydrobromobromic acid citricipran tablets (tablets, specifications: 20mg, chemical drugs)" has been reviewed and evaluated by the quality and efficacy of generic drugs.
the product as a treatment for depression, for the 2019 edition of the health insurance catalog Class B drugs.
, there are 8 domestic companies have the product production batch, Southwest Pharmaceuticals is the second company to obtain drug consistency evaluation approval.
it is worth mentioning that in the third batch of harvesting, Southwest Pharmaceuticals' "Brominate Sepran tablets" is to be selected for this collection.
announcement shows that the Southwest Pharmaceutical Industry to choose the "Brominate Syptopram tablets" specifications of 20mg, packaging quantity of 16 tablets / box, the proposed winning price of 39.45 yuan, the proposed winning number of 8.22 million tablets, to supply Sichuan, Beijing, Shanghai, Henan and other 16 provinces and autonomous regions.
, it is understood that the company's 2019 sales revenue of 2.97 million yuan, accounting for 0.03% of the company's sales revenue for the year.
This drug collection, such as confirmation of the winning bid, in the procurement cycle, medical institutions will give priority to use and ensure the completion of the agreed procurement volume, the follow-up will be conducive to enhance product competitiveness, improve market share and the company's brand influence.